In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area.
Judd W. Moul, MD
COUNTERPOINT—Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy?
Most men with clinically important localized prostate cancer deserve first-line open or robotic radical prostatectomy.
How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
A 66-year-old Caucasian man with a history of hypertension, hyperlipidemia, and rheumatoid arthritis was diagnosed with prostate cancer.
This management guide covers the treatment, diagnosis, and staging of prostate cancer.
This article reviews recent evidence suggesting an increased risk of pneumonia, cardiovascular disease, and acute kidney injury in men treated with ADT and consider whether the incidence of such events differs with the treatment modality.
The Urology Perspective on Expanding Androgen-Targeted Treatments for Men With Castration-Resistant Prostate Cancer
This is an exciting time for physicians who care for patients with advanced prostate cancer, and more importantly a time of heightened optimism for these men and their families.
Of course we should offer active surveillance to African-American men with localized prostate cancer! We simply need to do it selectively and in a smarter way—and we need to be aware of some of the potential pitfalls.
Over the last decade, robotic-assisted laparoscopic prostatectomy (RALP) has rapidly gained in popularity, primarily for three reasons: the enthusiasm of surgeons keen to try something new, medical marketing, and patients’ desire to avoid side effects from surgery.
These are, indeed, exciting times for patients with metastatic prostate cancer and the clinicians who care for them.